← Back to Search

Hyperpolarized 129XeMRI Imaging for Severe Asthma in Obesity

Phase 2
Recruiting
Led By Loretta Que, MD
Research Sponsored by Bastiaan Driehuys
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Asthma Cohort: Late onset asthma: Age of asthma onset (diagnosis) ≥12 years
Non-Asthma Cohort: Not currently smoking or using other forms of tobacco-related products (including vaping)
Must not have
Asthma Cohort: History of bronchial thermoplasty
Asthma Cohort: Chronic renal failure (creatinine > 2.0) at Visit 0
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group

Summary

This trial will use 3D imaging and RNA sequencing to study why obese asthmatics have more severe disease, in hopes of finding better ways to treat it.

Who is the study for?
This trial is for adults aged 18-65 with asthma and a BMI ≥30 kg/m2, who have been on stable asthma medication for at least 3 months. Non-smokers or those who haven't smoked in the last 3 months are eligible. Participants must be able to perform spirometry tests and give informed consent. Pregnant women, individuals with significant illnesses like heart disease or uncontrolled diabetes, or those unable to complete study assessments are excluded.
What is being tested?
The trial is studying how obesity affects severe asthma by using advanced imaging called Hyperpolarized 129XeMRI and single cell RNA sequencing. It aims to understand airway remodeling and fibrosis in obese asthmatics compared to lean ones, potentially leading to better treatments.
What are the potential side effects?
While not explicitly listed in the provided information, potential side effects may include discomfort from lying still during MRI scans, anxiety due to claustrophobia inside the MRI machine, allergic reactions if contrast agents are used, and minor bruising from blood draws.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My asthma was diagnosed when I was 12 years old or older.
Select...
I do not smoke or use tobacco/vaping products.
Select...
I have asthma and my BMI is 30 or higher.
Select...
I can do a breathing test as per standard guidelines.
Select...
I have been diagnosed with asthma for over a year.
Select...
I am between 18 and 65 years old and do not have asthma.
Select...
My BMI is 30 or higher and I do not have asthma.
Select...
I have never had asthma or other long-term lung problems.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have had bronchial thermoplasty for my asthma.
Select...
I have chronic kidney issues with creatinine levels above 2.0.
Select...
I have asthma and my sleep apnea has not been treated.
Select...
I have had 3 or more severe asthma attacks in the last year.
Select...
My kidney function is impaired with a creatinine level over 2.0.
Select...
I have sleep apnea that has not been treated.
Select...
I have not participated in any drug trials or had certain procedures for my asthma in the last 30 days.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Obese AsthmaticsExperimental Treatment1 Intervention
Obese patients that come to Duke that have been diagnosed with Asthma will be approached.
Group II: Obese Non-AsthmaticsActive Control1 Intervention
The obese non-asthmatics will be collected from an IRB pre-approved Healthy Volunteer Data Repository.

Find a Location

Who is running the clinical trial?

Bastiaan DriehuysLead Sponsor
14 Previous Clinical Trials
1,041 Total Patients Enrolled
National Institutes of Health (NIH)NIH
2,840 Previous Clinical Trials
8,172,583 Total Patients Enrolled
59 Trials studying Asthma
8,616 Patients Enrolled for Asthma
Loretta Que, MDPrincipal InvestigatorDuke
5 Previous Clinical Trials
197 Total Patients Enrolled
3 Trials studying Asthma
168 Patients Enrolled for Asthma

Media Library

Hyperpolarized 129XeMRI Clinical Trial Eligibility Overview. Trial Name: NCT04512547 — Phase 2
Asthma Research Study Groups: Obese Non-Asthmatics, Obese Asthmatics
Asthma Clinical Trial 2023: Hyperpolarized 129XeMRI Highlights & Side Effects. Trial Name: NCT04512547 — Phase 2
Hyperpolarized 129XeMRI 2023 Treatment Timeline for Medical Study. Trial Name: NCT04512547 — Phase 2
~0 spots leftby Jan 2025